Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.
about
Erythropoietin Pathway: A Potential Target for the Treatment of DepressionChallenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved TherapeuticsOptimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical PracticePharmacological approaches to the challenge of treatment-resistant depressionKetamine, sleep, and depression: current status and new questionsPractical clinical trials in psychopharmacology: a systematic reviewGoing beyond antidepressant monotherapy for incomplete response in nonpsychotic late-life depression: a critical reviewResponse prediction to antidepressants using scalp and source-localized loudness dependence of auditory evoked potential (LDAEP) slopes.Glutamate and its receptors in the pathophysiology and treatment of major depressive disorderS-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression.Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study)Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Enduring deficits in brain reward function after chronic social defeat in rats: susceptibility, resilience, and antidepressant responseDecreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder.MAOIs - does the evidence warrant their resurrection?Beyond serotonin: newer antidepressants in the future.Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group.Robust and sustained effect of ketamine infusions coadministered with conventional antidepressants in a patient with refractory major depression.Evidence-based treatment for depressive disorder.Polypharmacy or medication washout: an old tool revisitedToward a neuroimaging treatment selection biomarker for major depressive disorder.Depression treatment in patients with general medical conditions: results from the CO-MED trial.Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trialRoyal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.COMBINED MIRTAZAPINE AND SSRI TREATMENT OF PTSD: A PLACEBO-CONTROLLED TRIAL.Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatientsAre antidepressants effective in the acute and long-term treatment of depression? Sic et NonPioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients.Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 PatientsIs there anything really novel on the antidepressant horizon?Multi-modality: a new approach for the treatment of major depressive disorder.Ketamine as a novel antidepressant: from synapse to behavior.A review of antidepressant therapy in primary care: current practices and future directions.The Effect of Chronic Mild Stress and Imipramine on the Markers of Oxidative Stress and Antioxidant System in Rat Liver.
P2860
Q26750850-585BB8D3-09C7-4AC3-86D6-FFA261C666D0Q26782997-7E630B9B-B64E-4E5C-BDB1-DB989068CFA1Q26797416-4D5C7171-E6F8-4AC0-A17F-E6FC18DDBF2DQ26798241-1F22D113-D27F-4B1B-BAD1-1E7446AFD656Q26828564-A5DB8BEA-C0CE-4462-BF1C-B8D20203D776Q27021467-F9666027-5500-47BF-BB1F-E93B53FA45F3Q27022958-C087AB3B-7F32-4006-95EB-F0E021904FD7Q30435843-964DD772-070A-4D6E-BCD3-242FC1A1EEFCQ30711088-BBA856FE-4231-49B4-A2A1-0C2A993E07B0Q33614231-9920FAA9-1FBE-4CB8-9132-CC4FDC6FEE7EQ33625345-18338F9D-9475-40DA-B3AC-AAB0CEF38882Q33837167-B1288DBA-9C24-4BBD-AE01-E699C3112993Q33874459-254284FA-1A10-46AD-9FCE-755C18CEE93DQ33983943-C30055D9-3D61-45F2-B237-46F929BB7A05Q34181837-E1E76C8B-8FC5-49C8-B665-8ED5501C7354Q34515817-1FA8E61C-E1C7-4C2F-A240-D2346DF181B2Q34557706-A68D0439-D805-4738-ACBC-BDD09140C89DQ34640885-7EEF8716-C8E5-4304-B994-8267C29BF848Q35001345-998E4630-364E-4CDE-84A2-C066A4465015Q35122330-D29C3F3F-3609-4D72-9084-E78AE22BA345Q35169141-3569E343-FFB5-4B9D-BB11-1B1CACD7FD8DQ35190702-745B2807-12EF-4A24-928C-B39E66DB914CQ35330737-697422D2-9413-4433-A7C2-351C53480F88Q35548200-A0BDE18E-F13E-4165-9FA1-75372E818186Q35549737-916F349E-4879-4E9F-805D-9B40BE95D237Q35684146-35ED5214-FFE4-4266-8964-6226A3647DCEQ35740330-3B6B4A9F-B969-400B-B364-A6D89E42E8C7Q35862776-B2519CE1-AA6A-4C13-BD78-66925D13D4ADQ35886579-0E561DA2-629A-43F9-B4E0-24404C6549EAQ35889371-C7D0ADB9-A96C-4F55-BA73-B9B380F17BBCQ36024493-E93787AA-9813-4626-B5E5-11DA19695A05Q36100170-A326FF44-A558-472E-9DA9-3F4BEAE32EF6Q36100305-53A156DA-E525-47FF-8706-27DDA62CD65BQ36234571-4943AE30-EA7B-4D90-A860-1CE0CEBA8723Q36588313-612FBC25-4685-4927-87B4-5B3BC39E60C2Q36870889-E708EF1F-B48A-48C8-82FC-59EC07D81908Q36896252-18AFA737-8505-4FC6-B56A-94C7172B839BQ36905864-E286830D-DFDD-4D87-BA3D-6696D70F7EB3Q37070398-D6C3D800-AC45-470E-98EC-2FD1070BF4A9Q37099353-8356997B-AA14-44C3-AC56-73E749460DCD
P2860
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Combining medications to enhan ...... single-blind randomized study.
@en
Combining medications to enhance depression outcomes
@nl
type
label
Combining medications to enhan ...... single-blind randomized study.
@en
Combining medications to enhance depression outcomes
@nl
prefLabel
Combining medications to enhan ...... single-blind randomized study.
@en
Combining medications to enhance depression outcomes
@nl
P2093
P1476
Combining medications to enhan ...... single-blind randomized study
@en
P2093
Andrew A Nierenberg
Benji T Kurian
David W Morris
Diane Warden
Ian A Cook
Ira M Lesser
James F Luther
Jonathan W Stewart
Madhukar H Trivedi
Maurizio Fava
P304
P356
10.1176/APPI.AJP.2011.10111645
P407
P577
2011-05-02T00:00:00Z